Download PDF
Exp Clin Endocrinol Diabetes 2014; 122(09): 523-527
DOI: 10.1055/s-0034-1377005
Article
© J. A. Barth Verlag in Georg Thieme Verlag KG Stuttgart · New York

Safety Results from OCAPI: A European Observational Cohort Study of Insulin Glulisine-treated Children Aged 6–12 Years with Type 1 Diabetes

M. Konstantinova
1   University Paediatric Hospital, Sofia, Bulgaria
,
V. Loizeau
2   Lincoln, Boulogne-Billancourt, France
,
V. Pilorget
3   Sanofi, Paris, France
,
A. Cali
3   Sanofi, Paris, France
,
T. Danne
4   “Auf der Bult” Children and Youth Hospital, Hannover, Germany
› Author Affiliations
Further Information

Publication History

received 17 February 2014
first decision 17 February 2014

accepted 14 May 2014

Publication Date:
23 July 2014 (online)

Also available at
    Permissions and Reprints

Abstract

Objective: Data on the safety of insulin glulisine for type 1 diabetes are limited in paediatric populations. The European post-marketing Observational prospective Cohort study of children with type 1 diabetes treated with APIDRA® (OCAPI) study evaluated the safety of insulin glulisine in children aged 6–12 years in real-life clinical practice, with a particular focus on the 6–8 years age group.

Research design and methods: OCAPI was an international, multicentre, observational, non-interventional, prospective cohort study, in which 94 participants with type 1 diabetes (6–8 years age group: n=31; 9–12 years age group: n=63) received insulin glulisine for 6 months under normal, local conditions. The primary objective was the incidence of severe hypoglycaemia in all participants.

Results: Overall incidence of severe hypoglycaemia was 6.6 events per 100 persons/year (7.2 and 6.3 events per 100 persons/year in the 6–8 and 9–12 years age groups, respectively). 12 participants (all aged 9–12 years) experienced transient injection-site reactions. No systematic hypersensitivity reactions were reported. Only 1 participant (9–12 years age group) experienced a serious class-effect risk possibly related to insulin glulisine (severe hypoglycaemia requiring an Emergency Department visit). Glycated haemoglobin levels did not change markedly throughout the study, and were inversely proportional to the risk of hypoglycaemia.

Conclusions: Insulin glulisine has a good safety profile in children with type 1 diabetes aged 6–12 years, with generally low rates of severe hypoglycaemia and few adverse reactions. These results are encouraging for its use in paediatric populations.

Key words

diabetes mellitus - type 1 - children - insulin glulisine - safety - hypoglycaemia
 

  • References

  • 1 The Diabetes Control and Complications Trial Research Group . The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-986
    CrossrefPubMedSearch in Google Scholar
  • 2 Diabetes Control and Complications Trial Research Group . Effect of intensive diabetes treatment on the development and progression of long-term complications in adolescents with insulin-dependent diabetes mellitus: Diabetes Control and Complications Trial. J Pediatr 1994; 125: 177-188
    CrossrefPubMedSearch in Google Scholar
  • 3 Bergenstal RM, Tamborlane WV, Ahmann A et al Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes. N Engl J Med 2010; 363: 311-320
    Search in Google Scholar
  • 4 Braun D, Konrad D, Lang-Muritano M et al. Improved glycemic control and lower frequency of severe hypoglycemia with insulin detemir; long-term experience in 105 children and adolescents with type 1 diabetes. Pediatr Diabetes 2008; 9: 382-387
    CrossrefPubMedSearch in Google Scholar
  • 5 Bulsara MK, Holman CD, Davis EA et al. The impact of a decade of changing treatment on rates of severe hypoglycemia in a population-based cohort of children with type 1 diabetes. Diabetes Care 2004; 27: 2293-2298
    CrossrefPubMedSearch in Google Scholar
  • 6 Mortensen HB, Hougaard P. Comparison of metabolic control in a cross-sectional study of 2,873 children and adolescents with IDDM from 18 countries. The Hvidøre Study Group on Childhood Diabetes. Diabetes Care 1997; 20: 714-720
    CrossrefPubMedSearch in Google Scholar
  • 7 Nordfeldt S, Ludvigsson J. Severe hypoglycemia in children with IDDM. A prospective population study, 1992–1994. Diabetes Care 1997; 20: 497-503
    CrossrefPubMedSearch in Google Scholar
  • 8 O’Connell SM, Cooper MN, Bulsara MK et al. Reducing rates of severe hypoglycemia in a population-based cohort of children and adolescents with type 1 diabetes over the decade 2000–2009. Diabetes Care 2011; 34: 2379-2380
    CrossrefPubMedSearch in Google Scholar
  • 9 Philotheou A, Arslanian S, Blatniczky L et al. Comparable efficacy and safety of insulin glulisine and insulin lispro when given as part of a basal-bolus insulin regimen in a 26-week trial in pediatric patients with type 1 diabetes. Diabetes Technol Ther 2011; 13: 327-334
    CrossrefPubMedSearch in Google Scholar
  • 10 Rewers A, Chase HP, Mackenzie T et al. “French Predictors of acute complications in children with type 1 diabetes. JAMA 2002; 287: 2511-2518
    CrossrefPubMedSearch in Google Scholar
  • 11 Rosilio M, Cotton JB, Wieliczko MC et al. Factors associated with glycemic control. A cross-sectional nationwide study in 2,579 French children with type 1 diabetes. The French Pediatric Diabetes Group. Diabetes Care 1998; 21: 1146-1153
    CrossrefPubMedSearch in Google Scholar
  • 12 Wagner VM, Grabert M, Holl RW. Severe hypoglycaemia, metabolic control and diabetes management in children with type 1 diabetes in the decade after the Diabetes Control and Complications Trial – a large-scale multicentre study. Eur J Pediatr 2005; 164: 73-79
    CrossrefPubMedSearch in Google Scholar
  • 13 Dailey G, Rosenstock J, Moses RG et al. Insulin glulisine provides improved glycemic control in patients with type 2 diabetes. Diabetes Care 2004; 27: 2363-2368
    CrossrefPubMedSearch in Google Scholar
  • 14 Dreyer M, Prager R, Robinson A et al. Efficacy and safety of insulin glulisine in patients with type 1 diabetes. Horm Metab Res 2005; 37: 702-707
    Thieme ConnectPubMedSearch in Google Scholar
  • 15 Garg SK, Ellis SL, Ulrich H. Insulin glulisine: a new rapid-acting insulin analogue for the treatment of diabetes. Expert Opin Pharmacother 2005; 6: 643-651
    CrossrefPubMedSearch in Google Scholar
  • 16 Rayman G, Profozic V, Middle M. Insulin glulisine imparts effective glycaemic control in patients with type 2 diabetes. Diabetes Res Clin Pract 2007; 76: 304-312
    CrossrefPubMedSearch in Google Scholar
  • 17 Danne T, Becker RH, Heise T et al. Pharmacokinetics, prandial glucose control, and safety of insulin glulisine in children and adolescents with type 1 diabetes. Diabetes Care 2005; 28: 2100-2105
    CrossrefPubMedSearch in Google Scholar
  • 18 de Beaufort CE, Lange K, Swift PG et al. Metabolic outcomes in young children with type 1 diabetes differ between treatment centers: the Hvidoere Study in Young Children 2009. Pediatr Diabetes 2013; 14: 422-428
    CrossrefPubMedSearch in Google Scholar
  • 19 Tupola S, Komulainen J, Jaaskelainen J et al. Post-prandial insulin lispro vs. human regular insulin in prepubertal children with type 1 diabetes mellitus. Diabet Med 2001; 18: 654-658
    CrossrefPubMedSearch in Google Scholar
  • 20 Holcombe JH, Zalani S, Arora VK et al. Comparison of insulin lispro with regular human insulin for the treatment of type 1 diabetes in adolescents. Clin Ther 2002; 24: 629-638
    CrossrefPubMedSearch in Google Scholar
  • 21 Danne T, Philotheou A, Goldman D et al. A randomized trial comparing the rate of hypoglycemia-assessed using continuous glucose monitoring-in 125 preschool children with type 1 diabetes treated with insulin glargine or NPH insulin (the PRESCHOOL study). Pediatr Diabetes 2013; 14: 593-601
    CrossrefPubMedSearch in Google Scholar